2011/11/18 by Goran Rakočević, Mary Kay Floeter · 2 citations
Medicine · Neuroscience · #Autoimmune Neurological Disorders and Treatments #Genetic Neurodegenerative Diseases #Neurological disorders and treatments #Neuroscience #Stiff person syndrome #Autoantibody #Medicine #GABAergic #Electrophysiology #Inhibitory postsynaptic potential #Spinal cord #Mechanism (biology) #Etiology #Autoimmunity #Immune system #Immunology #Biology #Glutamate decarboxylase #Pathology #Antibody
paper · doi:10.1002/mus.23234
openalex publication_date 2011/11/18 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29
Stiff person syndrome (SPS) is a disabling autoimmune central nervous system disorder characterized by progressive muscle rigidity and gait impairment with superimposed painful spasms that involve axial and limb musculature, triggered by heightened sensitivity to external stimuli. Impaired synaptic GABAergic inhibition resulting from intrathecal B-cell-mediated clonal synthesis of autoantibodies against various presynaptic and synaptic proteins in the inhibitory neurons of the brain and spinal cord is believed to be an underlying pathogenic mechanism. SPS is most often idiopathic, but it can occur as a paraneoplastic condition. Despite evidence that anti-GAD and related autoantibodies impair GABA synthesis, the exact pathogenic mechanism of SPS is not fully elucidated. The strong association with several MHC-II alleles and improvement of symptoms with immune-modulating therapies support an autoimmune etiology of SPS. In this review, we discuss the clinical spectrum, neurophysiological mechanisms, and therapeutic options, including a rationale for agents that modulate B-cell function in SPS.